Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07118696 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease

Study acronym: RIFAstrat
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease severity.
Trial Details
NCT Number NCT07118696
Lead Sponsor Hamilton Health Sciences Corporation
Collaborators: St George's, University of London, McMaster University
Conditions
(from sponsor)		 Pulmonary TB
Related terms Tuberculosis, Pulmonary
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov